These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 36475702)
21. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways. Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665 [TBL] [Abstract][Full Text] [Related]
22. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study. Simonen P; Stenman UH; Gylling H Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271 [TBL] [Abstract][Full Text] [Related]
23. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. Le QT; Blanchet M; Seidah NG; Labonté P J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630 [TBL] [Abstract][Full Text] [Related]
24. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. Zhang DW; Lagace TA; Garuti R; Zhao Z; McDonald M; Horton JD; Cohen JC; Hobbs HH J Biol Chem; 2007 Jun; 282(25):18602-18612. PubMed ID: 17452316 [TBL] [Abstract][Full Text] [Related]
25. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465 [TBL] [Abstract][Full Text] [Related]
26. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Sun H; Samarghandi A; Zhang N; Yao Z; Xiong M; Teng BB Arterioscler Thromb Vasc Biol; 2012 Jul; 32(7):1585-95. PubMed ID: 22580899 [TBL] [Abstract][Full Text] [Related]
28. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916 [TBL] [Abstract][Full Text] [Related]
29. Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease. Venugopal J; Wang J; Guo C; Lu H; Chen YE; Eitzman DT Sci Rep; 2020 Oct; 10(1):16514. PubMed ID: 33020528 [TBL] [Abstract][Full Text] [Related]
30. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. Kosenko T; Golder M; Leblond G; Weng W; Lagace TA J Biol Chem; 2013 Mar; 288(12):8279-8288. PubMed ID: 23400816 [TBL] [Abstract][Full Text] [Related]
31. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms. Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780 [TBL] [Abstract][Full Text] [Related]
32. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor. Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967 [TBL] [Abstract][Full Text] [Related]
33. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. Luo Y; Warren L; Xia D; Jensen H; Sand T; Petras S; Qin W; Miller KS; Hawkins J J Lipid Res; 2009 Aug; 50(8):1581-8. PubMed ID: 19060325 [TBL] [Abstract][Full Text] [Related]
34. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. Bridge SH; Sheridan DA; Felmlee DJ; Crossey MM; Fenwick FI; Lanyon CV; Dubuc G; Seidah NG; Davignon J; Thomas HC; Taylor-Robinson SD; Toms GL; Neely RD; Bassendine MF J Hepatol; 2015 Apr; 62(4):763-70. PubMed ID: 25463543 [TBL] [Abstract][Full Text] [Related]
35. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045 [TBL] [Abstract][Full Text] [Related]
36. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Marais AD; Kim JB; Wasserman SM; Lambert G Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268 [TBL] [Abstract][Full Text] [Related]